Nasdaq IPOs

The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70% of the year's healt

Lemonade (LMND) launched its IPO on Thursday, in a deal set to raise $270 million next week by offering shares at a range of $23 to $26. Baillie Gifford plans to take down $100 million of the IPO (37%). At the $24.50 midpoint, the New York insurer would be valued at about $1.4 bi

Artius Acquisition, a blank check company formed by industry veterans targeting the tech sector, filed on Thursday with the SEC to raise up to $525 million in an initial public offering. The New York, NY-based company plans to raise $525 million by offering 52.5 million units at

Fusion Acquisition, a blank check company targeting the financial services industry, increased the proposed unit offering for its upcoming IPO on Thursday. The New York, NY-based company now plans to raise $300 million by offering 30 million units at $10. The company had previous

Akouos, a preclinical biotech developing gene therapies for inner ear disorders, raised the proposed deal size for its upcoming IPO on Thursday. The Boston, MA-based company now plans to raise $213 million by offering 12.5 million shares at an assumed offer price of $17. The comp

Lemonade, which provides online self-serve renters and homeowners insurance, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $270 million by offering 11 million shares at a price range of $23 to $26. At the midpoint of the proposed range, Le

Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering in the US. The pre-revenue company is currently listed in London on the AIM under the ticker RENX; it cl

iTeos Therapeutics, a Phase 1/2 oncology biotech, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. The company's lead candidate EOS-850, a highly selective small molecule antagonist of the adenosine A2a receptor (A2AR), is in an

Relay Therapeutics, a Phase 1 biotech developing small molecule therapies for solid tumors, filed on Wednesday with the SEC to raise up to $200 million in an initial public offering. The company's lead candidate RLY-1971, an inhibitor of Src homology region 2 domain-containing ph

Fusion Pharmaceuticals, a Phase 1 biotech developing precision medicines for solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Hamilton, Canada-based company now plans to raise $188 million by offering 12.5 million shares at a price range of $14 t

Fusion Pharmaceuticals, a Phase 1 biotech developing precision medicines for solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Hamilton, Canada-based company now plans to raise $188 million by offering 12.5 million shares at a price range of $14 t

The fourth-largest grocer in the US, Albertsons Companies (ACI) serves over 33 million customers per week through its 2,260 grocery stores. It operates under banners Albertsons, Safeway, Vons, Pavilions, Randalls, Tom Thumb, Carrs, Jewel-Osco, Acme, Shaw’s, Star Market, Uni

Dun & Bradstreet Holdings, which provides commercial data analytics services, announced terms for its IPO on Wednesday. In its latest filing, the company also added 16 underwriters. The Short Hills, NJ-based company plans to raise $1.3 billion by offering 65.8 million shares

Accolade, which provides a healthcare benefits management platform for self-insured employers, announced terms for its IPO on Wednesday. The Plymouth Meeting, PA-based company plans to raise $175 million by offering 8.8 million shares at a price range of $19 to $21. At the midpoi

Brilliant Acquisition, a blank check company targeting an Asia Pacific business, raised $40 million by offering 4 million units at $10. Each unit consists of one share of common stock, one warrant exercisable at $11.50, and one right to receive one-tenth a share of common stock.

Greenwich LifeSciences, a Phase 3 biotech developing immunotherapies for breast cancer, announced terms for its IPO on Tuesday. The Stafford, TX-based company plans to raise $21 million by offering 2.7 million shares (63% insider) at a price range of $7.50 to $8.50. At the midpoi

Pershing Square Tontine Holdings, a blank check company formed by Bill Ackman of Pershing Square targeting "Mature Unicorns," filed on Monday with the SEC to raise up to $3 billion in an initial public offering, which would make it the largest SPAC ever. To screen for upcoming or

Pershing Square Tontine Holdings, a blank check company formed by Bill Ackman of Pershing Square targeting "Mature Unicorns," filed on Monday with the SEC to raise up to $3 billion in an initial public offering, which would make it the largest SPAC ever. To screen for upcoming or

Pershing Square Tontine Holdings, a blank check company formed by Pershing Square targeting "Mature Unicorns," filed on Monday with the SEC to raise up to $3 billion in an initial public offering, making it the largest SPAC ever. The company plans to raise an additional $1 billio

ArcherDX, which provides genomic testing products for cancer, announced on Monday that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. ArcherDX originally filed for an IPO earlier this month with a proposed deal size of $100 million. The $1.4 billio